Teladoc Health (TDOC) is back in focus after its latest quarterly report, which showed lower Q2 revenue, a wider net loss, and reduced full year guidance. This has put profitability and growth plans under closer scrutiny.

Teladoc Health’s recent Q2 report and lowered 2026 guidance have coincided with a sharp pullback in the stock, with the 7 day share price return down 28.63% and the 1 year total shareholder return down 4.02%, reinforcing already weak longer term performance including a 5 year total shareholder return that has fallen 95.45%.

If Teladoc’s latest earnings have you rethinking where growth in virtual care and digital health might come from next, it can be useful to compare it against other healthcare focused AI players through our 41 healthcare AI stocks

After a slide that has taken Teladoc Health shares to about US$6.68, investors now face a choice: does this reset already reflect the weaker outlook, or does it make more sense to wait for a clearer entry point? The valuation numbers give some clues next.

Most Popular Narrative: 55.5% Undervalued

Against a last close of $6.68, the most followed Teladoc Health valuation narrative pegs fair value at $15.00 and treats today’s price as a steep discount.

Wall Street continues to price TDOC as an unprofitable, cash-burning "growth trap" trading at <0.5x EV/Sales and ~5x EV/EBITDA.

In reality, Teladoc is a cash-generative healthcare utility with: 1. $750M+ in hard cash protecting the downside. 2. $130M–$170M in annual free cash flow. 3. An expanding insurance-reimbursed mental health model.

Curious how this narrative gets from current losses to that higher fair value. It rests on cash generation, a changing revenue mix, and a very specific margin profile.

Result: Fair Value of $15.00 (UNDERVALUED)

However, Teladoc Health still faces real execution risk if BetterHelp’s insurance shift compresses margins or if telehealth competitors pull users and contracts away.

Next Steps

With Teladoc Health facing both pressure and potential, it helps to move quickly from headlines to the underlying data and form your own balanced view using the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Teladoc Health?

If Teladoc Health has you reassessing where to put your next dollar, do not sit on the sidelines while other opportunities line up on your radar.

• Target potential value opportunities by scanning companies that currently look mispriced using the 53 high quality undervalued stocks.
• Prioritise capital protection by reviewing companies that appear more resilient through the 82 resilient stocks with low risk scores.
• Hunt for under-covered potential by checking the screener containing 18 high quality undiscovered gems before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.